Another study looking at the value that specialty pharmaceuticals brings to employers and beyond found that:
Dollars spent on high-cost, specialty medications treating 3 chronic diseases (Rheumatoid Arthritis, Crohn’s, and Multiple Sclerosis) generate a direct return on investment to the employee’s plan-sponsoring employer, as well as indirectly to other employers, to the economy, and to the health care system.
Those benefits include reduced productivity losses, reduced disability costs, reduced need for caregiver resources, and reduced use and costs of healthcare resources.
The estimated benefits ranged from $6,600 to $17,000 per year, on average. But this does not include other intangible benefits like the ability of employers with a comprehensive and competitive benefit plan to recruit and retain employees.